Clinical Trial Update: Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) [Phase 2]

View source ↗

Summary

This Phase 2 trial tested mitoxantrone plus prednisone with sorafenib in taxane-refractory metastatic castration-resistant prostate cancer, and the study was te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Nexavar (Sorafenib)
• Novantrone (mitoxantrone)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Accelerated Community Oncology Research Network | Conditions: Metastatic Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2010-05-26